

From: Mizelle, Dezmona

Sent: 12/8/2014 11:17:34 AM

To: TTAB E Filing

CC:

Subject: U.S. TRADEMARK APPLICATION NO. 85924742 - MYRIAD MYRISK - 43043-3/146 - Request for Reconsideration Denied - Return to TTAB - Message 1 of 2

Attachment Information:

Count: 14

Files: mayo-01.jpg, mayo-02.jpg, mayo-03.jpg, mayo-04.jpg, mayo-05.jpg, mayo-06.jpg, mayo-07.jpg, mayo-08.jpg, mayo-09.jpg, mayo-10.jpg, mayo-11.jpg, mayo-12.jpg, mayo-13.jpg, 85924742.doc

**UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)
OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT'S TRADEMARK APPLICATION**

U.S. APPLICATION SERIAL NO. 85924742 MARK: MYRIAD MYRISK	
CORRESPONDENT ADDRESS: JOSHUA G GIGGER STOEL RIVES LLP 201 S MAIN ST STE 1100 SALT LAKE CITY, UT 84111	GENERAL TRADEMARK INFORMATION: http://www.uspto.gov/trademarks/index.jsp VIEW YOUR APPLICATION FILE
APPLICANT: Myriad Genetics, Inc.	
CORRESPONDENT'S REFERENCE/DOCKET NO: 43043-3/146 CORRESPONDENT E-MAIL ADDRESS: tm-slc@stoel.com	

REQUEST FOR RECONSIDERATION DENIED

ISSUE/MAILING DATE: 12/8/2014

The trademark examining attorney has carefully reviewed applicant's request for reconsideration and is denying the request for the reasons stated below. See 37 C.F.R. §2.64(b); TMEP §§715.03(a)(2)(B), (a)(2)(E), 715.04(a). The requirement(s) and/or refusal(s) made final in the Office action dated March 18, 2014 are maintained and continue to be final. See TMEP §§715.03(a)(2)(B), (a)(2)(E), 715.04(a).

In the present case, applicant's request has not resolved all the outstanding issue(s), nor does it raise a new issue or provide any new or compelling evidence with regard to the outstanding issue(s) in the final Office action. The refusal, as it relates to NICO MYRIAD has been withdrawn. With respect to the other marks, applicant's analysis and arguments are not persuasive nor do they shed new light on the issues. Accordingly, the request is denied.

LIKELIHOOD OF CONFUSION

Trademark Act Section 2(d) bars registration of an applied-for mark that so resembles a registered mark that it is likely a potential consumer would be confused, mistaken, or deceived as to the source of the goods and/or services of the applicant and registrant. See 15 U.S.C. §1052(d). A determination of likelihood of confusion under Section 2(d) is made on a case-by case basis and the factors set forth in *In re E. I. du Pont de Nemours & Co.*, 476 F.2d 1357, 177 USPQ 563 (C.C.P.A. 1973) aid in this determination. *Citigroup Inc. v. Capital City Bank Grp., Inc.*, 637 F.3d 1344, 1349, 98 USPQ2d 1253, 1256 (Fed. Cir. 2011) (citing *On-Line Careline, Inc. v. Am. Online, Inc.*, 229 F.3d 1080, 1085, 56 USPQ2d 1471, 1474 (Fed. Cir. 2000)). Not all the *du Pont* factors, however, are necessarily relevant or of equal weight, and any one of the factors may control in a given case, depending upon the evidence of record. *Citigroup Inc. v. Capital City Bank Grp., Inc.*, 637 F.3d at 1355, 98 USPQ2d at 1260; *In re Majestic Distilling Co.*, 315 F.3d 1311, 1315, 65 USPQ2d 1201, 1204 (Fed. Cir. 2003); see *In re E. I. du Pont de Nemours & Co.*, 476 F.2d at 1361-62, 177 USPQ at 567.

In this case, the following factors are the most relevant: similarity of the marks, similarity and nature of the goods and/or services, and similarity of the trade channels of the goods and/or services. See *In re Viterra Inc.*, 671 F.3d 1358, 1361-62, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); *In re Dakin's Miniatures Inc.*, 59 USPQ2d 1593, 1595-96 (TTAB 1999); TMEP §§1207.01 *et seq.*

In this case, the following factors are the most relevant: similarity of the marks, similarity of the goods and/or services, and similarity of trade channels of the goods and/or services. See *In re Opus One, Inc.*, 60 USPQ2d 1812 (TTAB 2001); *In re Dakin's Miniatures Inc.*, 59 USPQ2d 1593 (TTAB 1999); *In re Azteca Rest. Enters., Inc.*, 50 USPQ2d 1209 (TTAB 1999); TMEP §§1207.01 *et seq.*

COMPARISON OF THE MARKS

Marks are compared in their entireties for similarities in appearance, sound, connotation, and commercial impression. *Stone Lion Capital Partners, LP v. Lion Capital LLP*, 746 F.3d 1317, 1321, 110 USPQ2d 1157, 1160 (Fed. Cir. 2014) (quoting *Palm Bay Imps., Inc. v. Veuve Clicquot Ponsardin Maison Fondee En 1772*, 396 F. 3d 1369, 1371, 73 USPQ2d 1689, 1691 (Fed. Cir. 2005)); TMEP §1207.01(b)-(b)(v). “Similarity in any one of these elements may be sufficient to find the marks confusingly similar.” *In re Davia*, 110 USPQ2d 1810, 1812 (TTAB 2014) (citing *In re White Swan Ltd.*, 8 USPQ2d 1534, 1535 (TTAB 1988); *In re 1st USA Realty Prof’ls, Inc.*, 84 USPQ2d 1581, 1586 (TTAB 2007)); TMEP §1207.01(b).

Applicant’s mark is **MYRIAD MYRISK** for “medical test kits for detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with disease or risk of developing disease”. In International Class 10, and “medical testing, namely, providing reference and clinical laboratory tests which detect gene mutations, gene expression profiles or other molecular indicators or markers associated with disease or risk of developing disease; medical testing services for predicting disease and identifying risk factors of disease”, in International Class **44**.

REGISTRANT is providing:

MIRISK for medical laboratory services, in International Class 44.

MIRISK VP for medical laboratory services, and medical diagnostic testing and assessment services to determine patient’s risk of cardiovascular disease. International Class 42 and 44.

First, when comparing marks, the test is not whether the marks can be distinguished in a side-by-side comparison, but rather whether the marks are sufficiently similar in terms of their overall commercial impression that confusion as to the source of the goods and/or services offered under the respective marks is likely to result. *Midwestern Pet Foods, Inc. v. Societe des Produits Nestle S.A.*, 685 F.3d 1046, 1053, 103 USPQ2d 1435, 1440 (Fed. Cir. 2012); *In re Davia*, 110 USPQ2d 1810, 1813 (TTAB 2014); TMEP §1207.01(b). The proper focus is on the recollection of the average purchaser, who retains a general rather than specific impression of trademarks. *United Global Media Grp., Inc. v. Tseng*, 112 USPQ2d 1039, 1049, (TTAB 2014); *L’Oreal S.A. v. Marcon*, 102 USPQ2d 1434, 1438 (TTAB 2012); TMEP §1207.01(b).

Second, Although marks are compared in their entireties, one feature of a mark may be more significant or dominant in creating a commercial impression. See *In re Viterra Inc.*, 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); *In re Nat’l Data Corp.*, 753 F.2d 1056, 1058, 224 USPQ 749, 751 (Fed. Cir. 1985); TMEP §1207.01(b)(viii), (c)(ii). Greater weight is often given to this dominant feature when determining whether marks are confusingly similar. See *In re Nat’l Data Corp.*, 753 F.2d at 1058, 224 USPQ at 751.

Finally, the marks are similar. With respect to the MYRIAD MYRISK, MIRISK and MIRISK VP marks, they all contain the MIRISK/MYRISK, which are phonetic equivalents. Marks may be confusingly similar in appearance where similar terms or phrases or similar parts of terms or phrases appear in the compared marks and create a similar overall commercial impression. See *Crocker Nat'l Bank v. Canadian Imperial Bank of Commerce*, 228 USPQ 689, 690-91 (TTAB 1986), *aff'd sub nom. Canadian Imperial Bank of Commerce v. Wells Fargo Bank, Nat'l Ass'n*, 811 F.2d 1490, 1495, 1 USPQ2d 1813, 1817 (Fed. Cir. 1987) (finding COMMCASH and COMMUNICASH confusingly similar); *In re Corning Glass Works*, 229 USPQ 65, 66 (TTAB 1985) (finding CONFIRM and CONFIRMCELLS confusingly similar); *In re Pellerin Milnor Corp.*, 221 USPQ 558, 560 (TTAB 1983) (finding MILTRON and MILLTRONICS confusingly similar); TMEP §1207.01(b)(ii)-(iii). The additional wording of MYRIAD and VP is not sufficient

To prevent confusion between the marks.

COMPARISON OF THE GOODS AND SERVICES

The goods and/or services of the parties need not be identical or even competitive to find a likelihood of confusion. See *On-line Careline Inc. v. Am. Online Inc.*, 229 F.3d 1080, 1086, 56 USPQ2d 1471, 1475 (Fed. Cir. 2000); *Recot, Inc. v. Becton*, 214 F.3d 1322, 1329, 54 USPQ2d 1894, 1898 (Fed. Cir. 2000) (“[E]ven if the goods in question are different from, and thus not related to, one another in kind, the same goods can be related in the mind of the consuming public as to the origin of the goods.”); TMEP §1207.01(a)(i).

The respective goods and/or services need only be “related in some manner and/or if the circumstances surrounding their marketing [be] such that they could give rise to the mistaken belief that [the goods and/or services] emanate from the same source.” *Coach Servs., Inc. v. Triumph Learning LLC*, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting *7-Eleven Inc. v. Wechsler*, 83 USPQ2d 1715, 1724 (TTAB 2007)); TMEP §1207.01(a)(i).

Applicant is providing testing for medical purposes, namely, providing reference and clinical laboratory tests which detect gene mutations, gene expression profiles or other molecular indicators or markers associated with disease or risk of developing disease; medical testing services for predicting disease and identifying risk factors of disease

Registrant's are providing medical laboratory services, and medical diagnostic testing and assessment services to determine patient's risk of cardiovascular disease and medical laboratory services.

and vice versa. Further, registrant also performs diagnostic testing and risk assessment.

With respect to applicant's and registrant's goods and/or services, the question of likelihood of confusion is determined based on the description of the goods and/or services stated in the application and registration at issue, not on extrinsic evidence of actual use. *See Stone Lion Capital Partners, LP v. Lion Capital LLP*, 746 F.3d 1317, 1323, 110 USPQ2d 1157, 1162 (Fed. Cir. 2014) (quoting *Octocom Sys. Inc. v. Hous. Computers Servs. Inc.*, 918 F.2d 937, 942, 16 USPQ2d 1783, 1787 (Fed. Cir. 1990)).

It is noted that applicant has restricted their identification to exclude cardiovascular disease, however, in this case, the identification set forth in the registration(s) has no restrictions as to nature, type, channels of trade, or classes of purchasers. Therefore, it is presumed that these goods and/or services "travel in the same channels of trade to the same class of purchasers." *In re Viterra Inc.*, 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012) (quoting *Hewlett-Packard Co. v. Packard Press, Inc.*, 281 F.3d 1261, 1268, 62 USPQ2d 1001, 1005 (Fed. Cir. 2002)). Further, the registration's use(s) broad wording to describe the goods and/or services and this wording is presumed to encompass all goods and/or services of the type described, including those in applicant's more narrow identification. *See In re Jump Designs, LLC*, 80 USPQ2d 1370, 1374 (TTAB 2006) (citing *In re Elbaum*, 211 USPQ 639, 640 (TTAB 1981)).

Applicant's laboratory testing could include or encompass registrant's laboratory testing, and medical testing, a

The goods and/or services of the parties need not be identical or even competitive to find a likelihood of confusion. *See On-line Careline Inc. v. Am. Online Inc.*, 229 F.3d 1080, 1086, 56 USPQ2d 1471, 1475 (Fed. Cir. 2000); *Recot, Inc. v. Becton*, 214 F.3d 1322, 1329, 54 USPQ2d 1894, 1898 (Fed. Cir. 2000) ("[E]ven if the goods in question are different from, and thus not related to, one another in kind, the same goods can be related in the mind of the consuming public as to the origin of the goods."); TMEP §1207.01(a)(i).

The respective goods and/or services need only be "related in some manner and/or if the circumstances surrounding their marketing [be] such that they could give rise to the mistaken belief that [the goods and/or services] emanate from the same source." *Coach Servs., Inc. v. Triumph Learning LLC*, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting *7-Eleven Inc. v. Wechsler*, 83 USPQ2d 1715, 1724 (TTAB 2007)); TMEP §1207.01(a)(i).

The overriding concern is not only to prevent buyer confusion as to the source of the goods and/or services, but to protect the registrant from adverse commercial impact due to use of a similar mark by a

newcomer. See *In re Shell Oil Co.*, 992 F.2d 1204, 1208, 26 USPQ2d 1687, 1690 (Fed. Cir. 1993). Therefore, any doubt regarding a likelihood of confusion determination is resolved in favor of the registrant. TMEP §1207.01(d)(i); see *Hewlett-Packard Co. v. Packard Press, Inc.*, 281 F.3d 1261, 1265, 62 USPQ2d 1001, 1003 (Fed. Cir. 2002); *In re Hyper Shoppes (Ohio), Inc.*, 837 F.2d 463, 464-65, 6 USPQ2d 1025, 1025 (Fed. Cir. 1988).

The goods and services are related. The trademark examining attorney has attached evidence from the USPTO's X-Search database consisting of a number of third-party marks registered for use in connection with the same or similar goods and/or services as those of both applicant and registrant in this case. This evidence shows that the goods and/or services listed therein, namely, medical tools and medical kits and medical testing and medical laboratories, are of a kind that may emanate from a single source under a single mark. See *In re Anderson*, 101 USPQ2d 1912, 1919 (TTAB 2012); *In re Albert Trostel & Sons Co.*, 29 USPQ2d 1783, 1785-86 (TTAB 1993); *In re Mucky Duck Mustard Co.*, 6 USPQ2d 1467, 1470 n.6 (TTAB 1988); TMEP §1207.01(d)(iii).

In addition, see additional documents evidencing "medical laboratories" that perform both regular laboratory testing and medical testing for identifying risk factors. With the advent of more testing, specifically for identifying the "breast cancer" gene, more laboratories are moving towards including this type of testing within the routine testing.

In sum, the applicant's mark and registrants' mark create the same commercial impression and the goods and services are commercially related and likely to be encountered in the marketplace by consumers. Therefore, consumers are likely to be confused and mistakenly believe that the products originate from a common source. Therefore, registration remains refused based on Section 2(d) of the Lanham Act.

Also, please note that applicant has stated that registrant is bankrupt and the marks have abandoned. The marks have not abandoned on the Trademark Register. See *In re Calgon Corp.*, 435 F.2d 596, 168 USPQ 278 (C.C.P.A. 1971). Trademark Act Section 7(b), 15 U.S.C. §1057(b), provides that a certificate of registration on the Principal Register is prima facie evidence of the validity of the registration, of the registrant's ownership of the mark, and of the registrant's exclusive right to use the mark in commerce on or in connection with the goods and/or services specified in the certificate. During ex parte prosecution, the trademark examining attorney has no authority to review or to decide on matters that constitute a collateral attack on the cited registration. TMEP §1207.01(d)(iv).

Applicant argues that the cited marks are "weak marks". The Court of Appeals for the Federal Circuit and the Trademark Trial and Appeal Board have recognized that marks deemed "weak" or merely descriptive are still entitled to protection against the registration by a subsequent user of a similar mark for closely

related goods and/or services. *In re Colonial Stores, Inc.*, 216 USPQ 793, 795 (TTAB 1982); TMEP §1207.01(b)(ix); see *King Candy Co. v. Eunice King's Kitchen, Inc.*, 496 F.2d 1400, 1401, 182 USPQ 108, 109 (C.C.P.A. 1974). This protection extends to marks registered on the Supplemental Register. TMEP §1207.01(b)(ix); see, e.g., *In re Clorox Co.*, 578 F.2d 305, 307-08, 198 USPQ 337, 340 (C.C.P.A. 1978); *In re Hunke & Jochheim*, 185 USPQ 188 (TTAB 1975).

Applicant argues that the consumers in question are sophisticated purchasers. The fact that purchasers are sophisticated or knowledgeable in a particular field does not necessarily mean that they are sophisticated or knowledgeable in the field of trademarks or immune from source confusion. TMEP §1207.01(d)(vii); see, e.g., *Stone Lion Capital Partners, LP v. Lion Capital LLP*, 746 F.3d 1317, 1325, 110 USPQ2d 1157, 1163-64 (Fed. Cir. 2014); *Top Tobacco LP v. N. Atl. Operating Co.*, 101 USPQ2d 1163, 1170 (TTAB 2011).

The filing of a request for reconsideration does not extend the time for filing a proper response to a final Office action or an appeal with the Trademark Trial and Appeal Board (Board), which runs from the date the final Office action was issued/mailed. See 37 C.F.R. §2.64(b); TMEP §715.03, (a)(2)(B), (a)(2)(E), (c).

If time remains in the six-month response period to the final Office action, applicant has the remainder of the response period to comply with and/or overcome any outstanding final requirement(s) and/or refusal(s) and/or to file an appeal with the Board. TMEP §715.03(a)(2)(B), (c). However, if applicant has already filed a timely notice of appeal with the Board, the Board will be notified to resume the appeal. See TMEP §715.04(a).

/Dezmona J. Mizelle-Howard/

Dezmona J. Mizelle-Howard

Trademark Examining Attorney

Law Office 110

571.272.9368

Dezmona.Mizelle@Uspto.Gov



MayoACCESS

Search

Home

New User? Sign In

Test Utilization

Test Catalog

Clinical Specialties

- Cardiology
- Hematology
- Neurology
- Oncology
- Microbiology and Infectious Disease
- Genetics
 - Biochemical Genetics
 - Cytogenetics
 - Molecular Genetics**
- Pharmacogenomics
- Pediatrics
- Fertility

Test Ordering

Specimen Handling

Interpretive Handbook

Education

Outreach Resource Center

Test Updates

Customer Service

About Us



Molecular Genetics Laboratory

Test Index

The Molecular Genetics Laboratory provides expertise in DNA/molecular genetic testing for both congenital and inherited cancer syndromes. Our board certified laboratory directors are leaders in the field of genetic testing who continually strive to develop new test methods that improve patient care. In collaboration with laboratory technologists, supervisors and genetic counselors, they work to improve assays by increasing mutation detection rates and decreasing turn around time.



A

- Acute Porphyria, Multi-Gene Panel
 - Patient Information Form (required)

Alanine glyoxylate aminotransferase-(AGXT) Molecular Analysis

- AGXT Mutation Analysis (G170R)
- AGXT Gene, Full Gene Analysis
- AGXT Gene, Known Mutation
 - Patient Information Form (required for each test)

Alanine glyoxylate aminotransferase-(AGXT) Mutation Analysis

- Patient Information Form (required)

Alpha-1-Antitrypsin Genotype Profile

- Patient Information Form (required)

Alpha-Globin Gene Analysis-(Alpha-Thalassemia)

- Patient Information Form (required)

Amyloidosis, Transferrin-Associated Familial-DNA Sequence

- Patient Information Form (required)

Amyloidosis, Transferrin-Associated Familial Known Mutation

Sample Submission Information

- How To Order Tests

More Information

- The Molecular Genetics Laboratory
- Division of Laboratory Genetics

- Amyloidosis, Transthyretin-Associated Familial Known Mutation
 - Patient Information Form (required) 
- APC Gene Testing
 - Refer to FAP Mutation Screen or FAP Known Mutation
- Apolipoprotein A-I (APOA1) Gene, Full Gene Analysis
 - Patient Information Form (required) 
- Apolipoprotein A-I (APOA1) Gene, Known Mutation
 - Patient Information Form (required) 
- Apolipoprotein A-II (APOA2) Gene, Full Gene Analysis
 - Patient Information Form (required) 
- Apolipoprotein A-II (APOA2) Gene, Known Mutation
 - Patient Information Form (required) 
- Apolipoprotein E (APOE) Genotyping
 - Patient Information Form (required) 
- ARSA Gene, Full Gene Analysis
 - Patient Information Form (required) 
- ARSA Gene, Known Mutation
 - Patient Information Form (required) 
- Ashkenazi Jewish Mutation Analysis Panel Without Cystic Fibrosis
 - Patient Information Form (required) 
- Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis
 - Patient Information Form (required) 
- Autosomal Recessive Polycystic Kidney Disease (ARPKD), Known Mutation
 - Patient Information Form (required) 
- AXIN2 Gene, Full Gene Analysis
 - Patient Information Form (required) 
- AXIN2 Gene, Known Mutation
 - Patient Information Form (required) 

[▲ Top](#)

- B**
 - Beckwith-Wiedemann Syndrome (BWS)-Russell-Silver Syndrome (RSS) Molecular Analysis
 - Patient Information Form (required) 
 - Biotinidase Deficiency (BTD Gene), Full Gene Analysis
 - Patient Information Form (required) 

- Patient Information Form (required) 
- Biotinidase Deficiency (BTD Gene), Known Mutation**
- Patient Information Form (required) 
- Bloom Syndrome Mutation Analysis**
- Patient Information Form (required) 
- BMPR1A Gene, Full Gene Analysis**
- Patient Information Form (required) 
- BMPR1A Gene, Known Mutation**
- Patient Information Form (required) 
- BRAF Mutation Analysis (V600), Melanoma**
- Patient Information Form (required) 
- BRAF Mutation Analysis (V600E), Tumor**
- Patient Information Form (required) 
- Refer to the M1 H1-Hypermethylation/RRAF Mutation Analysis for additional tumor screening options.
- Refer to the HNPCC (Hereditary Nonpolyposis Colorectal Cancer)-Screen for MSI and IHC analyses.

[▲ Top](#)

C

- C9orf72 Hexanucleotide Repeat, Molecular Analysis**
- Patient Information Form (required) 
- Calcium Sensing Receptor (CASR) Gene, Known Mutation**
- Patient Information Form (required) 
- Calcium Sensing Receptor (CASR) Gene, Mutation Screen**
- Patient Information Form (required) 
- Canavan Disease Mutation**
- Patient Information Form (required) 
- Carnitine-Acylcarnitine Translocase Deficiency, Full Gene Analysis**
- Patient Information Form (required) 
- Carnitine-Acylcarnitine Translocase Deficiency, Known Mutation**
- Patient Information Form (required) 
- Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis**
- Patient Information Form (required) 
- Carnitine Palmitoyltransferase II Deficiency, Known Mutation**
- Patient Information Form (required) 

- Patient Information Form (required) 
- CDH1 Gene, Full Gene Analysis**
- Patient Information Form (required) 
- CDH1 Gene, Known Mutation**
- Patient Information Form (required) 
- CDKN1C Gene, Full Gene Analysis**
- Patient Information Form (required) 
- CDKN1C Gene, Known Mutation**
- Patient Information Form (required) 
- CHEK2 Gene, Full Gene Analysis**
- Patient Information Form (required) 
- CHEK2 Gene, Known Mutation**
- Patient Information Form (required) 
- CPOX Gene, Full Gene Analysis**
- Patient Information Form (required) 
- CPOX Gene, Known Mutation**
- Patient Information Form (required) 
- Cystic Fibrosis (CFTR) Molecular Analysis**
- Cystic Fibrosis Diagnosis and Carrier Detection Panel
- CFTR Gene, Full Gene Analysis
- CFTR Gene, Known Mutation
 - Patient Information Form (required for each test) 

[▲Top](#)

- D**
- Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis**
- Patient Information Form (required) 

[▲Top](#)

- E**
- EGFR Gene, Mutation Analysis, Tumor**

[▲Top](#)

- F**
- Fabry Disease, Full Gene Analysis**
- Patient Information Form (required) 

Fabry Disease, Known Mutation

- Patient Information Form (required) 

Familial Adenomatous Polyposis (FAP) Known Mutation

- Patient Information Form (required) 
- Communique Article 

Familial Adenomatous Polyposis (FAP) Mutation Screen

- Patient Information Form (required) 

Familial Dysautonomia Mutation Analysis

- Patient Information Form (required) 

Fanconi Anemia, Type C, Mutation Analysis

- Patient Information Form (required) 

Ferrochelatase (FECH) Gene, Full Gene Analysis

- Patient Information Form (required) 

Ferrochelatase (FECH) Gene, Known Analysis

- Patient Information Form (required) 

Fibrinogen Alpha-Chain (FGA) Gene, Full Gene Analysis

- Patient Information Form (required) 

Fibrinogen Alpha-Chain (FGA) Gene, Known Mutation

- Patient Information Form (required) 

FLG Gene, Mutation Analysis

- Patient Information Form (required) 

Fragile X Syndrome, Molecular Analysis

- Patient Information Form (required) 

Frontotemporal Dementia with Parkinsonism-17

- Refer to MAPT for test options

FTCD Gene, Full Gene Analysis

- Patient Information Form (required) 

FTCD Gene, Known Mutation

- Patient Information Form (required) 

[▲ Top](#)

G

Galactosemia (GALT) Gene Analysis

- Galactosemia Confirmation Test, Blood
- Galactosemia Gene Analysis (if mutation result)

- Galactosemia Gene Analysis (6 mutation panel)
- Galactosemia Gene Analysis, Known Mutation
- Galactosemia Gene, Full Gene Analysis
 - Patient Information Form (required for each test) 

- Gaucher Disease, Full Gene Analysis
 - Patient Information Form (required) 

- Gaucher Disease, Known Mutation
 - Patient Information Form (required) 

- Gaucher Disease, Molecular Analysis (Carrier Detection)
 - Patient Information Form (required) 

- Gelsolin (GSN) Gene, Full Gene Analysis
 - Patient Information Form (required) 

- Gelsolin (GSN) Gene, Known Mutation
 - Patient Information Form (required) 

- GNPTAB Gene, Full Gene Analysis
 - Patient Information Form (required) 

- GNPTAB Gene, Known Mutation
 - Patient Information Form (required) 

- Granulin
 - Refer to Progranulin Gene (GRN)

- GRHPR Gene, Full Gene Analysis
 - Patient Information Form (required) 

- GRHPR Gene, Known Mutation
 - Patient Information Form (required) 

[▲ Top](#)

H

- Hemochromatosis (HFE) Gene Analysis
 - Patient Information Form (required) 

- Hemophilia A, Molecular Analysis for Inversion, Diagnosis and Carrier Detection
 - Patient Information Form (required) 

- Hereditary Colon Cancer Del/Dup
 - Patient Information Form (required) 

- Hereditary Colon Cancer Panel
 - Patient Information Form (required) 

- Patient Information Form (required) 
- Hereditary Pancreatitis
 - Patient Information Form (required) 
- Hereditary Pancreatitis, Known Mutation
 - Patient Information Form (required) 
- HMBS Gene, Full Gene Analysis
 - Patient Information Form (required) 
- HMBS Gene, Known Mutation
 - Patient Information Form (required) 
- HNPCC (Hereditary Nonpolyposis Colorectal Cancer) - Screen (Tumor Testing for MSI and IHC)
 - Patient Information Form (required) 
 - Communiqué Article 
 - Refer to Microsatellite Instability Only, Tumor-(MSI Only) for stand alone analysis.
 - Refer to MLH1, MSH2, or MSH6 for germline testing information.
 - Refer to the MLH1-Hypermethylation/BRAF Mutation Analyses for additional tumor screening options.
- HOXB13 Mutation Analysis (GB4E)
 - Patient Information Form (required) 
- Hunter Syndrome, Full Gene Analysis
 - Patient Information Form (required) 
- Hunter Syndrome, Known Mutation
 - Patient Information Form (required) 
- Huntington Disease, Molecular Analysis
 - Patient Information Form (required) 
- Hurler Syndrome, Full Gene Analysis
 - Patient Information Form (required) 
- Hurler Syndrome, Known Mutation
 - Patient Information Form (required) 
- Hyperoxyluria
 - Refer to Alanine glyoxylate aminotransferase (AGXT) Mutation Analysis

[Top](#)

- Immunohistochemistry
 - Refer to HNPCC Screen
 - Communiqué Article 

- [Communique Article](#)
- IVD (Isovaleryl-CoA Dehydrogenase), Mutation Analysis
 - [Patient Information Form \(required\)](#)

[▲Top](#)

K

- Krabbe Disease, Full Gene Analysis and Large (30 kb) Deletion, PCR
 - [Patient Information Form \(required\)](#)
- Krabbe Disease, Known Mutation
 - [Patient Information Form \(required\)](#)
- KRAS Mutation Analysis, Colorectal
 - [Patient Information Form \(required\)](#)
- KRAS Mutation Analysis, Other
 - [Patient Information Form \(required\)](#)

[▲Top](#)

L

- Lung Cancer, EGFR with ALK Reflex
 - [Patient Information Form \(required\)](#)
 - [Lung Cancer, EGFR with ALK reflex, Tumor Algorithm](#)
- Lysozyme (LYZ) Gene, Full Gene Analysis
 - [Patient Information Form \(required\)](#)
- Lysozyme (LYZ) Gene, Known Mutation
 - [Patient Information Form \(required\)](#)

[▲Top](#)

M

- MAPT Known Mutation
 - [Patient Information Form \(required\)](#)
- MAPT Screening Sequence Analysis
 - [Patient Information Form \(required\)](#)
- Maternal Cell Contamination, Molecular Analysis
- MECP2 Gene, Full Gene Analysis
 - [Patient Information Form \(required\)](#)
- MECP2 Gene, Known Mutation
 - [Patient Information Form \(required\)](#)

Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency, Known Mutation

- Patient Information Form (required) 

Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Mutation Screen

- Patient Information Form (required) 

Methylmalonic Aciduria and Homocystinuria, cbC type, Full Gene Analysis

- Patient Information Form (required) 

Methylmalonic Aciduria and Homocystinuria, cbC type, Known Gene Analysis

- Patient Information Form (required) 

Methylmalonic Aciduria and Homocystinuria, cbD Type, Full Gene Analysis

- Patient Information Form (required) 

Methylmalonic Aciduria and Homocystinuria, cbD Type, Known Mutation

- Patient Information Form (required) 

Microsatellite Instability Only, Tumor (MSI Only)

- Patient Information Form (required) 
- Refer to HNPCC Screen for MSI/IHC testing
- Communiqué Article 

MLH1 Hypermethylation Analysis, B

- Patient Information Form (required) 

MLH1 Hypermethylation and BRAF Mutation Analyses, Tumor

- Patient Information Form (required) 
- Refer to the MLH1-Hypermethylation Analysis or BRAF Mutation Analysis for stand alone analysis.
- Refer to the HNPCC (Hereditary Nonpolyposis Colorectal Cancer)-Screen for MSI and IHC analyses.

MLH1 Hypermethylation Analysis, Tumor

- Patient Information Form (required) 
- Refer to the MLH1-Hypermethylation/BRAF Mutation Analyses for additional tumor screening options.
- Refer to the HNPCC (Hereditary Nonpolyposis Colorectal Cancer)-Screen for MSI and IHC analyses.

MLH1-Known Mutation

- Patient Information Form (required) 
- Communiqué Article 

MLH1/MSH2 Mutation Screen

- Patient Information Form (required) 

MLH1-Mutation Screen

- Patient Information Form (required) 
- Communiqué Article 

- Refer to HNPCC Screen for MSI/HC testing
- MLH3 Gene, Full Gene Analysis
 - Patient Information Form (required) 
- MLH3 Gene, Known Mutation
 - Patient Information Form (required) 
- MLYCD Gene, Full Gene Analysis
 - Patient Information Form (required) 
- MLYCD Gene, Known Mutation
 - Patient Information Form (required) 
- MPS IIIA, Full Gene Analysis
 - Patient Information Form (required) 
- MPS IIIA, Known Mutation
 - Patient Information Form (required) 
- MPS IIIB, Full Gene Analysis
 - Patient Information Form (required) 
- MPS IIIB, Known Mutation
 - Patient Information Form (required) 
- MPSVI, Full Gene Analysis
 - Patient Information Form (required) 
- MPSVI, Known Mutation
 - Patient Information Form (required) 
- MSH2-Known Mutation
 - Patient Information Form (required) 
 - Communiqué Article 
- MSH2-Mutation Screen
 - Patient Information Form (required) 
 - Communiqué Article 
 - Refer to HNPCC Screen for MSI/HC testing
- MSH6-Known Mutation
 - Patient Information Form (required) 
 - Communiqué Article 
- MSH6-Mutation Screen
 - Patient Information Form (required) 
 - Communiqué Article 
 - Refer to HNPCC Screen for MSI/HC testing

Mucopolidosis IV Mutation Analysis

- Patient Information Form (required) 

Multiple Endocrine Neoplasia Type 2-Mutation Screen (2A, 2B, FMTC)

- Patient Information Form (required) 

Multiple Endocrine Neoplasia Type 2-Known Mutation (2A, 2B, FMTC)

- Patient Information Form (required) 

MYH Gene Analysis for Multiple Adenoma

- Patient Information Form (required) 
- Communiqué Article 

[▲Top](#)

N

Niemann-Pick Disease, Types A and B, Full Gene Analysis

- Patient Information Form (required) 

Niemann-Pick Disease, Types A and B, Known Mutation

- Patient Information Form (required) 

Niemann-Pick Disease, Types A and B, Mutation Analysis

- Patient Information Form (required) 

Niemann-Pick Type C Disease, Known Mutation

- Patient Information Form (required) 

Niemann-Pick Type C, Full Gene Analysis

- Patient Information Form (required) 

[▲Top](#)

P

PMS2 Gene, Full Gene Analysis

- Patient Information Form (required) 

PMS2 Gene, Known Mutation

- Patient Information Form (required) 

Pompe Disease, Full Gene Sequencing

- Patient Information Form (required) 

Pompe Disease, Known Mutation

- Patient Information Form (required) 

PPOX Gene, Full Gene Analysis

- Patient Information Form (required) 

- PPOX Gene, Known Mutation
 - Patient Information Form (required) 
- Prader-Willi/Angelman Syndrome, Molecular Analysis
 - Patient Information Form (required) 
- Progranulin Gene (GRN), Full Gene Analysis
 - Patient Information Form (required) 
- Progranulin Gene (GRN), Known Mutation
 - Patient Information Form (required) 
- PTEN Gene, Full Gene Analysis
 - Patient Information Form (required) 
- PTEN Gene, Known Mutation
 - Patient Information Form (required) 

[▲ Top](#)

R

- Rett Syndrome
 - Refer to MECP2 for test options

[▲ Top](#)

S

- SEPT9 Gene, Known Mutation
 - Patient Information Form (required) 
- SEPT9 Gene, Mutation Screen
 - Patient Information Form (required) 
- Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency Known Mutation
 - Patient Information Form (required) 
- Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency Mutation Screen
 - Patient Information Form (required) 
- Single-gene Large Del/Dup
 - Patient Information Form (required) 
- SMAD4 Gene, Full Gene Analysis
 - Patient Information Form (required) 
- SMAD4 Gene, Known Mutation
 - Patient Information Form (required) 

Specimen Source Identification

- Patient Information Form (required) 

Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis

- Patient Information Form (required) 

STK11 Gene, Full Gene Analysis

- Patient Information Form (required) 

STK11 Gene, Known Mutation

- Patient Information Form (required) 

SUMF1 Gene, Full Gene Analysis

- Patient Information Form (required) 

SUMF1 Gene, Known Mutation

- Patient Information Form (required) 

[▲Top](#)

T

Tay-Sachs Disease (HEXA), Mutation Analysis

- Tay-Sachs Diagnosis and Carrier Detection Panel
- Tay-Sachs Disease HEXA Gene, Full Gene Analysis
- Tay-Sachs Disease HEXA Gene, Known Mutation
 - Patient Information Form (required for each test) 
 - Communiqué Article 

TP53 Gene, Full Gene Analysis

- Patient Information Form (required) 

TP53 Gene, Known Mutation

- Patient Information Form (required) 

[▲Top](#)

U

UBE3A Gene, Full Gene Analysis

- Patient Information Form (required) 

UBE3A Gene, Known Mutation

- Patient Information Form (required) 

Uniparental Disomy-(UPD)

- Parental specimens required. If specimens are not available, please contact the laboratory, 1-800-533-1710
- Patient Information Form (required) 

[▲Top](#)